September 26, 2006 -- Millennium Pharma offered $515 million to buy fellow cancer drug company, AnorMED of Canada; EpiCept reported Azixa was effective in an early trial against metastasized brain cancer; CytRx said arimoclomol was not effective against ALS; Mindray priced above the range and moved higher still in open trading; Cephalon won FDA approval of a pain drug; Sanofi-Aventis began trials of a flu vaccine that uses a cell-based manufacturing technology; Alnylam out-licensed its RNAi technology to Quark Biotech; CV Therapeutics said its Phase III study of Ranexa will move into its close-out phase; and Indevus discusessed trial design with FDA for its stuttering therapy. The Centient Biotech 200™ gained 7 points to 3761.42, a rise of .18%. More details...
